{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T03:22:50Z","timestamp":1771039370991,"version":"3.50.1"},"reference-count":44,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,4,3]],"date-time":"2023-04-03T00:00:00Z","timestamp":1680480000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Surg."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Therapeutic treatment for advanced-stage (T<jats:sub>2<\/jats:sub>\u2013T<jats:sub>4<\/jats:sub>) gastroesophageal junction (GEJ) and gastric cancer involves neoadjuvant chemotherapy with subsequent surgical intervention.<\/jats:p><\/jats:sec><jats:sec><jats:title>Method<\/jats:title><jats:p>Neoadjuvant oncological treatment for GEJ and gastric cancer previously consisted of the intravenous administration of epirubicin, cisplatin and fluorouracil (ECF) or epirubicin, cisplatin and capecitabine (ECX) combination (Group 1). The new protocol (FLOT, F: 5-FU, L: leucovorin, O: oxaliplatin, T: docetaxel), included patients with resectable GEJ and gastric cancer who had a clinical stage cT<jats:sub>2<\/jats:sub> or higher nodal positive cN+ disease (Group 2). Between 31 December 2008 and 31 October 2022, the effect of different oncological protocols in terms of surgical outcomes in cases of T<jats:sub>2<\/jats:sub>\u2013T<jats:sub>4<\/jats:sub> tumours were retrospectively evaluated. Results of randomly assigned patients from the earlier ECF\/ECX protocol (<jats:italic>n<\/jats:italic>\u2009=\u200936) (Group 1) and the new FLOT protocol (<jats:italic>n<\/jats:italic>\u2009=\u200952) (Group 2) were compared. Effect of different neoadjuvant therapies on tumour regression, types of possible side effects, type of surgery, and oncological radicality of surgical procedures were analysed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>When comparing the two groups, we found that in case of the FLOT neoadjuvant chemotherapy (Group 2, <jats:italic>n<\/jats:italic>\u2009=\u200952), complete regression was achieved in 13.95% of patients, whereas in the case of ECF\/ECX (Group 1, <jats:italic>n<\/jats:italic>\u2009=\u200936), complete regression occurred in only 9.10% of patients. Furthermore, in the FLOT group, the mean number of lymph nodes removed was slightly higher (24.69 vs. 20.13 in the ECF\/ECX group). In terms of the safety resection margin (proximal), no significant difference was found between the two treatment groups. Nausea and vomiting were the most common side effects. The occurrence of diarrhea was significantly higher in the FLOT group (<jats:italic>p<\/jats:italic>\u2009=\u20090.006). Leukopenia and nausea occurred more commonly with the old protocol (Group 1). The rate of neutropenia was lower following FLOT treatment (<jats:italic>p<\/jats:italic>\u2009=\u20090.294), with the lack of grade II and III cases. Anaemia occured at a significantly higher rate (<jats:italic>p<\/jats:italic>\u2009=\u20090.036) after the ECF\/ECX protocol.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>As a result of the FLOT neoadjuvant oncological protocol for advanced gastro-esophageal junction and gastric cancer, the rate of complete tumour regression increased significantly. The rate of side effects was also appreciably lower following the FLOT protocol. These results strongly suggest a significant advantage of the FLOT neoadjuvant treatment used before surgery.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fsurg.2023.1148984","type":"journal-article","created":{"date-parts":[[2023,4,3]],"date-time":"2023-04-03T05:01:40Z","timestamp":1680498100000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Impact of neoadjuvant FLOT treatment of advanced gastric and gastroesophageal junction cancer following surgical therapy"],"prefix":"10.3389","volume":"10","author":[{"given":"Attila","family":"Paszt","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zsolt","family":"Simonka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krisztina","family":"Budai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zoltan","family":"Horvath","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marton","family":"Erdos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marton","family":"Vas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aurel","family":"Ottlakan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tibor","family":"Nyari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zoltan","family":"Szepes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriella","family":"Uhercsak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aniko","family":"Maraz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laszlo","family":"Torday","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laszlo","family":"Tiszlavicz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Judit","family":"Olah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gyorgy","family":"Lazar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,4,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.3748\/wjg.v28.i12.1187","article-title":"Epidemiology of stomach cancer","volume":"28","author":"Ilic","year":"2022","journal-title":"World J Gastroenterol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"101404","DOI":"10.1016\/j.eclinm.2022.101404","article-title":"The current and future incidence and mortality of gastric cancer in 185 countries, 2020\u201340: a population-based modelling study","volume":"47","author":"Morgan","year":"2022","journal-title":"EClinicalMedicine"},{"key":"B3","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.semradonc.2012.09.008","article-title":"Epidemiology and risk factors for gastroesophageal junction tumors: understanding the rising incidence of this disease","volume":"23","author":"Buas","year":"2013","journal-title":"Semin Radiat Oncol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1556\/MaSeb.62.2009.2.1","article-title":"Surgical treatment for early Barrett cancer","volume":"62","author":"Horv\u00e1th","year":"2009","journal-title":"Magy Seb"},{"key":"B5","first-page":"25","article-title":"Cardia cancer: attempt at a therapeutically relevant classification","volume":"58","author":"Siewert","year":"1987","journal-title":"Chirurg"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1046\/j.1365-2168.1998.00940.x","article-title":"Classification of adenocarcinoma of the oesophagogastric junction","volume":"85","author":"Siewert","year":"1998","journal-title":"Br J Surg"},{"key":"B7","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1634\/theoncologist.1-4-210","article-title":"Multimodality therapy for esophageal cancer","volume":"1","author":"Siewert","year":"1996","journal-title":"Oncologist"},{"key":"B8","doi-asserted-by":"publisher","first-page":"855","DOI":"10.6004\/jnccn.2019.0033","article-title":"Esophageal and esophagogastric junction cancers, version 2.2019 NCCN clinical practice guidelines in oncology","volume":"17","author":"Ajani","year":"2019","journal-title":"J Natl Compr Canc Netw"},{"key":"B9","doi-asserted-by":"publisher","first-page":"567529","DOI":"10.3389\/fonc.2020.567529","article-title":"Feasibility and safety of perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel for locally advanced gastric cancer patients in China","volume":"10","author":"Sah","year":"2021","journal-title":"Front Oncol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1007\/s12032-016-0774-4","article-title":"A pilot trial of FLOT neoadjuvant chemotherapy for resectable esophagogastric junction adenocarcinoma","volume":"33","author":"Al-Fakeeh","year":"2016","journal-title":"Med Oncol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1200\/JCO.2010.33.0597","article-title":"Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial","volume":"29","author":"Ychou","year":"2011","journal-title":"J Clin Oncol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"2074","DOI":"10.1056\/NEJMoa1112088","article-title":"Preoperative chemoradiotherapy for esophageal or junctional cancer","volume":"366","author":"van Hagen","year":"2012","journal-title":"N Engl J Med"},{"key":"B13","doi-asserted-by":"publisher","first-page":"15806","DOI":"10.1038\/s41598-019-52334-y","article-title":"Systematic review and meta-analysis of docetaxel perioperative chemotherapy regimens in gastric and esophagogastric tumors","volume":"9","author":"Uson Junior","year":"2019","journal-title":"Sci Rep"},{"key":"B14","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1097\/CCO.0000000000000630","article-title":"Multimodality treatment for localized gastric cancer: state of the art and new insights","volume":"32","author":"Petrillo","year":"2020","journal-title":"Curr Opin Oncol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s11864-019-0654-1","article-title":"Optimizing therapies in the perioperative management of gastric cancer","volume":"20","author":"Khan","year":"2019","journal-title":"Curr Treat Options Oncol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa055531","article-title":"Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer","volume":"355","author":"Cunningham","year":"2006","journal-title":"N Engl J Med"},{"key":"B17","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1007\/s00595-019-01843-4","article-title":"True esophagogastric junction adenocarcinoma: background of its definition and current surgical trends","volume":"50","author":"Kumamoto","year":"2020","journal-title":"Surg Today"},{"key":"B18","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1111\/nyas.14454","article-title":"Current surgical treatment standards for esophageal and esophagogastric junction cancer","volume":"1482","author":"Jung","year":"2020","journal-title":"Ann NY Acad Sci"},{"key":"B19","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1111\/j.1442-2050.2012.01350.x","article-title":"Comparison of the prognostic value of the 6th and 7th editions of the union for international cancer control TNM staging system in patients with lower esophageal cancer undergoing neoadjuvant chemotherapy followed by surgery","volume":"26","author":"Mehta","year":"2013","journal-title":"Dis Esophagus"},{"key":"B20","doi-asserted-by":"publisher","first-page":"60","DOI":"10.6004\/jnccn.2013.0009","article-title":"Impact of the 7th edition AJCC staging classification on the NCCN clinical practice guidelines in oncology for gastric and esophageal cancers","volume":"11","author":"Strong","year":"2013","journal-title":"J Natl Compr Canc Netw"},{"key":"B21","doi-asserted-by":"publisher","first-page":"S2671","DOI":"10.21037\/jtd.2018.03.182","article-title":"Clinical implication of the innovations of the 8th edition of the TNM classification for esophageal and esophago-gastric cancer","volume":"10","author":"D\u2019Journo","year":"2018","journal-title":"J Thorac Dis"},{"key":"B22","doi-asserted-by":"publisher","first-page":"5192","DOI":"10.21037\/jtd.2018.08.98","article-title":"Is the new distribution of early esophageal adenocarcinoma stages improving the prognostic prediction of the 8th edition of the TNM staging system for esophageal cancer?","volume":"10","author":"Mo","year":"2018","journal-title":"J Thorac Dis"},{"key":"B23","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.soc.2022.07.006","article-title":"The perioperative and operative management of esophageal and gastric cancer","volume":"32","author":"Siddiqi","year":"2023","journal-title":"Surg Oncol Clin N Am"},{"key":"B24","first-page":"1019","article-title":"Short-term efficacy and safety of the synchronous neoadjuvant chemoradiotherapy with paclitaxel plus carboplatin in stage III adenocarcinoma of esophagogastric junction","author":"Ji","year":"2018","journal-title":"Zhonghua Wei Chang Wai Ke Za Zhi"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-022-04096-w","article-title":"Body composition dynamics and impact on clinical outcome in gastric and gastro-esophageal junction cancer patients undergoing perioperative chemotherapy with the FLOT protocol","author":"Huemer","year":"2022","journal-title":"J Cancer Res Clin Oncol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1007\/s11605-019-04511-7","article-title":"Operative results and perioperative morbidity after intensified neoadjuvant chemotherapy with FLOT for gastroesophageal adenocarcinoma impact of intensified neoadjuvant treatment","volume":"25","author":"Ganschow","year":"2021","journal-title":"J Gastrointest Surg"},{"key":"B27","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1186\/s12885-022-09623-z","article-title":"Perioperative treatment in resectable gastric cancer with spartalizumab in combination with fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT): a phase II study (GASPAR)","volume":"22","author":"Dos Santos","year":"2022","journal-title":"BMC Cancer"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1200\/JCO.2009.25.4706","article-title":"Multicenter phase III comparison of cisplatin\/S-1 with cisplatin\/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial","volume":"28","author":"Ajani","year":"2010","journal-title":"J Clin Oncol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1186\/s12885-021-08872-8","article-title":"Preventive HIPEC in combination with perioperative FLOT versus FLOT alone for resectable diffuse type gastric and gastroesophageal junction type II\/III adenocarcinoma - the phase III \u201cPREVENT\"- (FLOT9) trial of the AIO \/CAOGI \/ACO","volume":"21","author":"G\u00f6tze","year":"2021","journal-title":"BMC Cancer"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/dote.12480","article-title":"Worldwide trends in surgical techniques in the treatment of esophageal and gastroesophageal junction cancer","volume":"30","author":"Haverkamp","year":"2017","journal-title":"Dis Esophagus."},{"key":"B31","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1016\/j.ejso.2019.07.022","article-title":"FREGAT Working group\u2014FRENCH. Adenocarcinoma of the oesophagogastric junction Siewert II: an oesophageal cancer better cured with total gastrectomy","volume":"45","author":"Voron","year":"2019","journal-title":"Eur J Surg Oncol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1186\/s12885-020-07152-1","article-title":"The CARDIA-trial protocol: a multinational, prospective, randomized, clinical trial comparing transthoracic esophagectomy with transhiatal extended gastrectomy in adenocarcinoma of the gastroesophageal junction (GEJ) type II","volume":"20","author":"Leers","year":"2020","journal-title":"BMC Cancer"},{"key":"B33","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s10120-019-01022-x","article-title":"Esophagogastric junction adenocarcinomas: individualization of resection with special considerations for Siewert type II, and Nishi types EG, E\u2009=\u2009G and GE cancers","volume":"23","author":"H\u00f6lscher","year":"2020","journal-title":"Gastric Cancer"},{"key":"B34","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1007\/s10120-015-0466-3","article-title":"Long-term quality of life after surgery for adenocarcinoma of the esophagogastric junction: extended gastrectomy or transthoracic esophagectomy?","volume":"19","author":"Fuchs","year":"2016","journal-title":"Gastric Cancer"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1002\/bjs.8931","article-title":"Effects of hybrid minimally invasive oesophagectomy on major postoperative pulmonary complications","volume":"99","author":"Briez","year":"2012","journal-title":"Br J Surg"},{"key":"B36","doi-asserted-by":"publisher","first-page":"4957","DOI":"10.1007\/s00464-018-6257-2","article-title":"Total minimally invasive esophagectomy for esophageal adenocarcinoma reduces postoperative pain and pneumonia compared to hybrid esophagectomy","volume":"32","author":"Berlth","year":"2018","journal-title":"Surg Endosc"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1016\/j.surg.2015.08.019","article-title":"Early outcome of thoracoscopic and hybrid esophagectomy: propensity-matched comparative analysis","volume":"159","author":"Bonavina","year":"2016","journal-title":"Surgery"},{"key":"B38","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1097\/SLA.0000000000002445","article-title":"Defining benchmarks for transthoracic esophagectomy: a multicenter analysis of total minimally invasive esophagectomy in low risk patients","volume":"266","author":"Schmidt","year":"2017","journal-title":"Ann Surg"},{"key":"B39","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1097\/00000658-200009000-00007","article-title":"Adenocarcinoma of the esophagogastric junction: results of surgical therapy based on anatomical\/topographic classification in 1,002 consecutive patients","volume":"232","author":"R\u00fcdiger Siewert","year":"2000","journal-title":"Ann Surg"},{"key":"B40","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1097\/01.sla.0000145925.70409.d7","article-title":"Three-field lymphadenectomy for carcinoma of the esophagus and gastroesophageal junction in 174 R0 resections: impact on staging, disease-free survival, and outcome: a plea for adaptation of TNM classification in upper-half esophageal carcinoma","volume":"240","author":"Lerut","year":"2004","journal-title":"Ann Surg"},{"key":"B41","doi-asserted-by":"publisher","first-page":"5609","DOI":"10.1245\/s10434-022-11922-5","article-title":"Al population-based cohort study from a prospective national registry: better long-term survival in esophageal cancer after minimally invasive compared with open transthoracic esophagectomy","volume":"29","author":"Hayami","year":"2022","journal-title":"Ann Surg Oncol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"doz060","DOI":"10.1093\/dote\/doz060","article-title":"Robot-assisted minimally invasive esophagectomy (RAMIE) compared to conventional minimally invasive esophagectomy (MIE) for esophageal cancer: a propensity-matched analysis","volume":"33","author":"Tagkalos","year":"2020","journal-title":"Dis Esophagus"},{"key":"B43","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1111\/nyas.13676","article-title":"Surgical robotics for esophageal cancer","volume":"1434","author":"Grimminger","year":"2018","journal-title":"Ann N Y Acad Sci"},{"key":"B44","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.bpg.2018.11.004","article-title":"Robot assisted minimally invasive esophagectomy (RAMIE) for esophageal cancer","author":"van der Sluis","year":"2018","journal-title":"Best Pract Res Clin Gastroenterol"}],"container-title":["Frontiers in Surgery"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fsurg.2023.1148984\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,3]],"date-time":"2023-04-03T05:01:44Z","timestamp":1680498104000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fsurg.2023.1148984\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,3]]},"references-count":44,"alternative-id":["10.3389\/fsurg.2023.1148984"],"URL":"https:\/\/doi.org\/10.3389\/fsurg.2023.1148984","relation":{},"ISSN":["2296-875X"],"issn-type":[{"value":"2296-875X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,3]]},"article-number":"1148984"}}